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Background: The goal of asthma management focuses on adequate control of asthma,
although little is known about the optimal level of asthma control to be reached. The ELIOS
study was conducted in France to address this lack of information.
Methods: Cross-sectional study of asthmatic children (4e15 years) visiting their medical practi-
tioner. The primary objective was to assess the level of asthma control with a 3-level composite
score based on French (ANAES) guidelines criteria (optimal, acceptable, and unacceptable).
Results: Asthma control was assessed in 3431 children and classified as optimal (26%), acceptable
(41.3%), and unacceptable (32.7%). When PEFR was studied, asthma control was optimal in 23.0%,
acceptable in 35.8% and unacceptable in 41.2% (p< 0.001) of children. Unacceptable asthma
control was significantly associated with higher BMI (pZ 0.002), more recent diagnosis of asthma
(pZ 0.008), passive exposure to parental tobacco smoke (p< 0.001), number of associated
allergic diseases (p< 0.001), frequent respiratory tract infections (p< 0.001) and low socioeco-
nomic status (p< 0.001). Multivariate analysis identified presence of respiratory tract infections
(p< 0.0001), passive exposure to parental tobacco smoke (pZ 0.009) and low socioeconomic
status (pZ 0.042) as variables associated with unacceptable asthma control.
Conclusions: There is room for improvement in France as only 25% of asthmatic children are opti-
mally controlled. Public health strategies should increase awareness among physicians and
parents about the importance of using asthma control tools, eliminating exposure to tobacco
smoke and treating associated allergic diseases.
ª 2009 Elsevier Ltd. All rights reserved.48 38; fax: þ44 38 17 40.
.fr (J. de Blic).
9 Elsevier Ltd. All rights reserved.
1384 J. de Blic et al.Introduction history, treatment and control. Peak expiratory flow rateTable 1 Criteria for acceptable asthma control according
to the ANAES (HAS) guidelines.4
Variable Threshold
Daytime symptoms <4 days/week
Nighttime symptoms <1 night/week
Physical activity Normal
Exacerbations Mild and infrequent
Absenteeism from
work or school
None
Use of symptomatic b2
agonist treatment
<4 doses/week
FEV1 or PEFR >85% of the best value
obtained by the individual
Daily variation in PEFR <15%
PEFR, peak expiratory flow rate.Asthma is the most common chronic illness encountered in
children and adolescents. In 1994e1995, the ISAAC (Inter-
national Study of Asthma and Allergies in Childhood) study
estimated the prevalence of childhood asthma in France
from 9.3% in the 6e7 years old to 12.6% in the 13e14 years
old.1 A recent French survey estimated the prevalence at
12.7% in children aged 11e14 years.2
The goal of asthma treatment is to achieve and maintain
clinical control, defined as patients having a normal life-
style with no limitations in their activities and a normal
pulmonary function (www.ginasthma.org).3 The National
Canadian consensus and more recently the French national
health observatory (ANAES, now named Haute Autorite´ de
Sante´; HAS) proposed guidelines for care of adults and
adolescents with asthma aged at least 12 years.4 These
defined asthma control by eight parameters, namely
daytime symptoms, night-time symptoms, exacerbations,
use of short acting b2-agonists, social functioning, physical
activity and respiratory function (forced expiratory volume
in 1 s (FEV1), peak expiratory flow rate (PEFR) and daily
variation of PEFR). GINA 2007 proposed a five-component
programme to optimise asthma control.3 This consisted of
(1) developing a patient/doctor partnership, (2) identifying
and reducing exposure to risk factors, (3) assessing, treat-
ing and monitoring asthma, (4) managing asthma exacer-
bations and (5) special considerations. The majority of
international and national guidelines focus on medication
use, control of the environment and health education.3,4
There is still room for improvement in standards of
routine care proposed to children with asthma in Europe,
since asthma control, as recommended by the guidelines has
been shown to be satisfactory in less than 30% of children.5,6
Current asthma guidelines focus on treatment manage-
ment to obtain the optimal control. To achieve this goal, it
is important to improve the knowledge on asthma control at
the population level. To address these issues, we conducted
an observational study, ELIOS, in primary care in France.
The primary objective of this study was to assess the level
of asthma control in children aged between 4 and 15 years,
and to investigate potential risk factors for unacceptable
control.
Methods
The ELIOS study was a cross-sectional, observational study
performed in France between March and August 2005. A
total of 1800 general practitioners, 400 community-based
paediatricians and 400 community-based chest specialists
were chosen randomly from a national physician registry to
participate in the study.
Each participating physician was invited to include, the
first three children consulting for asthma and fulfilling the
entry inclusion criteria. The entry inclusion criteria were 1)
children aged between 4 and 15 years and 2) having an
asthma diagnosed for at least one year. Were excluded: 1)
children participating in another study and 2), children or
parents unable to read.
At study entry, and for each child, the investigator
completed a questionnaire about demographic data, asthma(PEFR), was performed at the discretion of the investigator.
Body mass index in kg/m2 was assessed from the height and
the weight, then categorized as underweight, normal,
overweight and obese according to age standards proposed
by Cole et al.7
Asthma control was assessed for the previous four weeks
using the criteria proposed by the ANAES in September
20044 (Table 1), defining three levels of asthma control:
namely optimal (no asthma symptoms and normal lung
function), acceptable (all ANAES criteria fulfilled) and
unacceptable (at least one ANAES criterion unfulfilled)
control. Exacerbations were indirectly estimated by school
absenteeism due to asthma.
Information on parents’ health insurance coverage was
also collected. In France, the national health insurance
(Se´curite´ Sociale) is considered as the standard coverage,
and it pays for approximately 70% of healthcare expendi-
ture. People are encouraged, either on an individual basis or
through their employer, to get an additional coverage from
a private insurer to make up for the difference. However,
households with no identified source of income for extended
periods are eligible for a full reimbursement from the
national health insurance. This government plan, Cou-
verture Me´dicale Universelle (CMU), can be considered as
a marker of low socio-economic status or social exclusion.
Statistical analysis
Analysis was performed in all children with asthma who had
their asthma control assessed (nZ 3431). Further analyses
compared 2 subgroups of children, one corresponded to the
subsets of children with (nZ 1306) and without (nZ 2125)
a valid PEFR measurement (Fig. 1). A comparative analysis
was also performed on the subgroup of 1306 children,
whether the PEFR criterion was taken into account or not.
Study variables are presented as mean values, standard
deviation, median and range for quantitative variables, and
numbers of subjects with percentages for categorical vari-
ables. Inter-group comparisons were performed using
analysis of variance or the Wilcoxon test for quantitative
variables, Fisher’s exact test for qualitative variables and
not ordinal variables, and KruskaleWallis test for ordinal
variables.
Participating physicians
N = 1787
Included children
N = 4402
Assessed children
N = 3431
1471 GPs
111 Chest specialists
204 Paediatricians
Without PEFR measured
N = 2125
With PEFR measured
N = 1306
Insuffisient data
N = 971 
PEFR: peak expiratory flow rate
Figure 1 Flow chart of study participants and study
population.
Asthma control in children: ELIOS survey findings 1385The variables reported on the questionnaire were
assessed for association with the level of asthma control. In
a first step, each variable was evaluated independently in
a univariate analysis. Two analyses were performed, the
first compared test variables with the three levels of
control (optimal, acceptable and unacceptable) and the
second with two levels of control (optimal versus accept-
able/unacceptable). Levels of control were attributed to
clinical criteria only without considering the lung function
parameter. In the next step, all variables associated with
the level of asthma control at a probability level of 0.2 in
any of the univariate analyses were entered into a multiple
logistic regression analysis in which variables were retained
in the model in an increasing stepwise manner in order to
determine those variables that were independently asso-
ciated with the level of asthma control at a probability
level of 0.05. The variables retained were entered into
a final multivariate model to generate odds ratios. A
sensitivity analysis was performed in the subgroup of chil-
dren that had respiratory function testing, with the levels
of control being reassigned to take the lung function into
account.
All analyses were performed using SAS software version
8.2 (SAS, Cary, USA) on UNIX hardware.
Results
Of the 4443 children included by 1787 participating physi-
cians (Fig. 1), 3431 (78.4%) could be assessed for asthma
control. A successful peak expiratory flow measure was
available for 1306 children (38.1% of those assessed).
Characteristics of the study population
The socio-demographic and clinical characteristics of chil-
dren assessed are presented in Tables 2 and 3. The mean age
was 9.8 years, two thirds were boys, 69.5 % had at least one
co-morbid allergic disease, 19.8 % were overweight or
obese, 35.2 % were passive smokers and 37.3% had a house-
hold pet. The group of excluded children did not differ from
the assessed group except for age (mean age 9.4 years),pets at home (42.5%) and smoker at home (39.8%). Children
in the PEFR group were older, had a longer duration of
asthma, more frequently multiple allergic diseases, and
were more likely to have a normal body mass index.
Asthma control
Clinical criteria of asthma control and asthma control levels
are detailed in Table 3. Over half of the sample reported
daytime (54.0%) or night-time (51.2%) asthma symptoms,
15.1% had interference with physical activities, and 14.1%
missed school. Daytime asthma symptoms (pZ 0.012) and
interference with physical activities (pZ 0.011) were more
frequently observed in the PEFR group.
For the overall study population (nZ 3431), asthma
control was clinically assessed as optimal in 26.0%,
acceptable in 41.3% and unacceptable in 32.7%. A better
level of asthma control was observed in children followed
by a chest specialist (Table 4).
In the subgroup of children for whom data on PEFR were
available (nZ 1306), asthma control differed significantly
(p< 0.001) whether the PEFR criterion was taken into
account or not (p< 0.001). Asthma control was significantly
overestimated in the absence of PEFR in 7.0% of patients.
Asthma treatments
A maintenance treatment was prescribed to 2859 children,
i.e., 83.3% of study population: 71.2% were prescribed an
inhaled corticosteroid, either alone or in combination with
a long-acting b2-agonist (Table 5). Forty-three (1.5%) chil-
dren had been prescribed a short-acting b2-agonist alone as
a control therapy, and 4.7% a leukotriene antagonist alone.
Associated allergy-related treatments were prescribed
to 1744 children (50.3%), most frequently antihistamines
(1541 children; 44.5%) or nasal corticosteroids (517 chil-
dren; 14.9%).
Variables associated with asthma control
The significant associations determined by univariate
analyses are displayed in Table 6. Poorer asthma control
was associated with higher BMI, more recent diagnosis of
asthma, family history of asthma, presence of a smoker in
the household, number of associated allergic diseases,
frequency of respiratory tract infections, and low socio-
economic status. When the analysis was repeated for
optimal control, the same variables were found except for
the duration of asthma and the unemployment of parents.
In addition, the level of asthma control varied according to
the asthma maintenance treatment received (p< 0.001):
46% of children with an optimal control received fixed
combinations of inhaled corticosteroids and long-acting b2-
agonists vs. 29% in children with an unacceptable control
(Fig. 2).
The multivariate analyses identified respiratory tract
infections ORZ 3.92 [3.00; 5.14], duration of asthma
ORZ 0.96 [0.92; 0.99], number of allergic diseases
(ORZ 1.42 [1.14; 1.77] for one, ORZ 1.88 [1.44; 2.45] for
two and ORZ 3.76 [2.30; 6.14] for three), tobacco passive
smoking ORZ 1.82 [1.49; 2.23] and eligibility for CMU free
Table 2 Sociodemographic characteristics of the study population.
All subjects
(nZ 3431)
Subjects without
PEFR (nZ 2125)
Subjects with PEFR
(nZ 1306)
p
Age (years)
Mean SD 9.8 3.1 9.5 3.2 10.3 2.9 <0.001
4e5 years 366 (10.7%) 284 (13.4%) 82 (6.3%)
6e11 years 1846 (53.9%) 1141 (53.8%) 705 (54.1%)
12e15 years 1212 (35.4%) 695 (32.8%) 517 (39.7%)
Missing data 7 5 2
Gender
Boys 2251 (65.7%) 1374 (64.8%) 877 (67.2%) 0.17
Girls 1174 (34.3%) 745 (35.2%) 429 (32.8%)
Missing data 6 6 None
Body mass
Underweight 145 (4.3%) 97 (4.8%) 48 (3.7%) 0.025
Normal 2518 (75.3%) 1513 (74.1%) 1005 (77.3%)
Overweight 465 (13.9%) 280 (13.7%) 185 (14.2%)
Obese 216 (6.5%) 153 (7.5%) 63 (4.8%)
Missing data 87 82 5
Associated allergic diseases
None 1046 (30.5%) 695 (32.7%) 351 (26.9%) <0.001
One 1509 (44.0%) 931 (43.8%) 578 (44.3%)
Two 683 (19.9%) 390 (18.4%) 293 (22.4%)
Three 161 (4.7%) 93 (4.4%) 68 (5.2%)
Four 32 (0.9%) 16 (0.8%) 16 (1.2%)
Mean number of allergic diseases SD 1.02 0.88 0.97 0.87 1.10 0.90 <0.001
Type of allergy
Allergic rhinitis 1805 (52.6%) 1060 (49.9%) 745 (57.0%) <0.001
Atopic dermatitis 751 (21.9%) 444 (20.9%) 307 (23.5%) 0.074
Allergic conjunctivitis 702 (20.5%) 410 (19.3%) 292 (22.4%) 0.033
Food allergies 228 (6.7%) 140 (6.6%) 88 (6.7%) 0.888
Respiratory tract infections 642 (18.7%) 411 (19.3%) 231 (17.7%) 0.241
Missing data None None None
Familial history of asthma 1668 (49.5%) 1013 (48.5%) 655 (51.1%) 0.136
Missing data 59 34 25
Parents consider child allergic 2601 (76.3%) 1558 (73.8%) 1043 (80.2%) <0.001
Missing data 12 15 6
Presence of a smoker
in the household
1200 (35.2%) 751 (35.5%) 449 (34.6%) 0.580
Missing data 18 11 7
Presence of a pet in the household 1257 (37.3%) 772 (37.0%) 485 (37.8%) 0.660
Missing data 65 41 24
CMU health insurance cover 379 (11.2%) 236 (11.2%) 143 (11.0%) 0.867
Missing data 31 23 8
Profession of parents
Agricultural worker 230 (6.7%) 145 (6.9%) 85 (6.5%) 0.726
Self-employed 435 (12.8%) 255 (12.1%) 180 (13.9%) 0.139
Salaried professional 688 (20.2%) 416 (19.7%) 272 (20.9%) 0.404
Managerial 903 (26.5%) 556 (26.3%) 347 (26.7%) 0.842
White collar worker 1428 (41.9%) 898 (42.5%) 530 (40.8%) 0.317
Blue-collar worker 576 (16.9%) 357 (16.9%) 219 (16.9%) 1.00
Unemployed 1048 (30.7%) 664 (31.5%) 384 (29.5%) 0.252
Quantitative variables are presented as mean values standard deviation and categorical variables as number of children (%).
PEFR, peak expiratory flow rate.
The probability values (p) represent differences between children with and without PEFR measurements.
Table 3 Clinical characteristics of the study population.
All subjects
(nZ 3 431)
Subjects without PEFR
(nZ 2 125)
Subjects with PEFR
(nZ 1 306)
p
Duration of asthma (years) 4.7 2.7 4.5 2.7 5.0 2.7 <0.001
Missing data 34 21 13
Asthma impact in previous 4 weeks
No daytime symptoms 1577 (46.0%) 995 (46.8%) 582 (44.6%)
Daytime symptoms< 4 times a week 1541 (44.9%) 957 (45.0%) 584 (44.7%) 0.035
Daytime symptoms 4 times a week 313 (9.1%) 173 (8.1%) 140 (10.7%)
No night-time symptoms 1673 (48.8%) 1058 (49.8%) 615 (47.1%)
Night-time symptoms< once a week 1194 (34.8%) 724 (34.1%) 470 (36.0%) 0.303
Night-time symptoms once a week 564 (16.4%) 343 (16.1%) 221 (16.9%)
Interference with physical activities 519 (15.1%) 295 (13.9%) 224 (17.2%) 0.011
School absenteeism 485 (14.1%) 302 (14.2%) 183 (14.0%) 0.880
No need for SABA 1307 (38.1%) 844 (39.7%) 463 (35.5%)
<4 doses SABA a week needed 1485 (43.3%) 900 (42.4%) 585 (44.8%) 0.041
4 doses SABA a week needed 639 (18.6%) 381 (17.9%) 258 (19.8%)
Missing data None None None
PEF< .085% of theoretical value 216 (16.5%)
Level of asthma control
Optimal 892 (26.0%) 572 (26.9%) 320 (24.5%) 0.212
Acceptable 1416 (41.3%) 876 (41.2%) 540 (41.4%) 0.035
Unacceptable 1123 (32.7%) 677 (31.9%) 446 (34.2%)
Quantitative variables are presented as mean values standard deviation and categorical variables as number of children (%).
PEFR, peak expiratory flow rate. SABA, short-acting beta2-agonist.
The probability values (p) represent differences between children with and without PEFR measurements.
Table 5 Asthma maintenance treatment received by
children included in the study.
Type of maintenance treatment NZ 2859
Fixed ICS and LABA combinations 1301 (45.5%)
Open ICS and LABA combinations 105 (3.7%)
Asthma control in children: ELIOS survey findings 1387health insurance coverage ORZ 1.63 [1.20; 2.21] as vari-
ables associated with unacceptable asthma control.
The results differed in the PEFR subgroup as BMI, dura-
tion of asthma and professional status of the parents were
not associated as univariate variables. The multivariate
analysis showed that respiratory tract infections ORZ 3.37
[2.16; 5.27] and eligibility for CMU health insurance
coverage ORZ 1.84 [1.10; 3.07] remained independent
variables for unacceptable control in addition to allergic
rhinitis (ORZ 1.58 [1.18; 2.12]) and tobacco passive
smoking ORZ 2.15 [1.35. 3.40].
Discussion
This was a large study with 4443 children, of whom 3431
were evaluable for their level of asthma control. Data
from this study show that the level of clinical controlTable 4 Level of asthma control according to speciality of
caregivers.
Level of
asthma
control
General
practitioners
(nZ 2781)
Paediatricians
(nZ 298)
Chest
specialists
(nZ 190)
Optimal 702 (25.2%) 83 (27.9%) 65 (34.2%)
Acceptable 1179 (42.4%) 105 (35.2%) 66 (34.7%)
Unacceptable 900 (32.4%) 110 (36.9%) 59 (31.1%)
The level of control differed significantly between groups
according to speciality of the caregiver (Fisher’s exact test,
p< 0.009), i.e., optimal control was more frequently encoun-
tered in patients followed by a chest specialist.remains largely unsatisfactory in children in France, with
less than one quarter of children having an optimal control
and a third being unacceptably controlled. Our results also
emphasise the importance of an ambulatory lung function
test (PEFR) as a parameter to be included in the evalua-
tion of asthma control, and identify variables associated
with poor asthma control, namely frequent respiratory
tract infections, number of associated allergic diseases,
passive smoking, low socio-economic status and body mass
index.ICS monotherapy 629 (22.0%)
LABA monotherapy 68 (2.4%)
LT antagonist monotherapy 133 (4.7%)
SABA monotherapy 43 (1.5%)
Other open combinations
(e.g., ICSþ LT, LABAþ LT)
563 (19.7%)
Others (e.g., oral corticosteroids,
caffeine derivatives)
17 (0.6%)
Treatment groups combine children with or without prescrip-
tions for short-acting b2-agonists. ICS, inhaled corticosteroids;
LABA, long-acting b2-agonists; LT, leukotriene and SABA, short-
acting b2-agonists. Percentages are calculated with respect to
the total number of children having received an identified
control therapy (2859 children). Data were missing for 49
children.
Table 6 Univariate analysis of factors associated with the level of asthma control.
Variable Level of control p
Optimal (NZ 892) Acceptable (NZ 1416) Unacceptable (NZ 1123)
Mean age SD (years) 9.9 3.1 9.9 3.0 9.6 3.3 0.154
Missing data 1 4 2
Gender
Boys 562 (25.0%) 948 (42.1%) 741 (32.9%) 0.124
Girls 330 (28.1%) 464 (39.5%) 380 (32.4%)
Missing data None 4 2
Body mass index
Underweight 30 (20.7%) 64 (44.1%) 51 (35.2%) 0.002
Normal 706 (28.0%) 1014 (40.3%) 798 (31.7%)
Overweight 107 (23.0%) 201 (43.2%) 157 (33.8%)
Obese 36 (16.7%) 95 (44.0%) 85 (39.4%)
Missing data 13 42 32
Smoker in household 242 (20.2%) 489 (40.8%) 469 (39.1%) <0.001
Missing data 6 9 3
CMU health insurance cover 78 (20.6%) 134 (35.4%) 167 (44.1%) <0.001
Missing data 5 11 15
Profession of parent
Agricultural worker 48 (20.9%) 95 (41.3%) 87 (37.8%) 0.112
Self-employed 129 (29.7%) 165 (37.9%) 141 (32.4%) 0.153
Professional 198 (28.8%) 292 (42.4%) 198 (28.8%) 0.034
Managerial 254 (28.1%) 379 (42.0%) 270 (29.9%) 0.072
White collar worker 363 (25.4%) 597 (41.8%) 468 (32.8%) 0.755
Blue-collar worker 129 (22.4%) 243 (42.2%) 204 (35.4%) 0.075
Unemployed 272 (26.0%) 402 (38.4%) 374 (35.7%) 0.032
Duration of asthma (year) 4.80 2.65 4.77 2.73 4.51 2.68
Missing data 11 15 8 0.008
Associated allergic diseases
None 320 (30.6%) 413 (39.5%) 313 (29.9%) <0.001
One 388 (25.7%) 657 (43.5%) 464 (30.8%)
Two 153 (22.4%) 278 (40.7%) 252 (36.9%)
Three 25 (15.5%) 56 (34.8%) 80 (49.7%)
Four 6 (18.8%) 12 (37.5%) 14 (43.8%)
Mean number of allergies SD 0.89 0.83 1.01 0.85 1.13 0.94 <0.001
Type of allergy
Allergic rhinitis 417 (23.1%) 750 (41.6%) 638 (35.4%) <0.001
Atopic dermatitis 172 (22.9%) 319 (42.5%) 260 (34.6%) 0.088
Allergic conjunctivitis 155 (22.1%) 268 (38.2%) 279 (39.7%) <0.001
Food allergies 49 (21.5%) 92 (40.4%) 87 (38.2%) 0.127
Respiratory tract Infections 81 (12.6%) 241 (37.5%) 320 (49.8%) <0.001
Parents consider child allergic 646 (24.9%) 1088 (41.8%) 867 (33.3%) <0.001
Missing data 2 11 8
Familial history of asthma 407 (24.4%) 687 (41.2%) 574 (34.4%) 0.034
Missing data 15 19 25
Variables significantly associated (p< 0.2) with the level of asthma control identified in univariate analysis. For this analysis, PEFR was
not taken into account. Quantitative variables are presented as mean values standard deviation and categorical variables as number of
children (%). Percentages are calculated with respect to control level (rows). Probability values were determined with the c2 test,
KruskaleWallis test or Fisher’s exact test, as appropriate. SD, standard deviation.
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* 0% for optimal control, 1% for acceptable and 2.7% for unacceptable control 
** 1.6% for optimal control, 1.8% for acceptable and 2.6% for unacceptable control 
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Figure 2 Level of asthma control according to asthma
maintenance treatment. The level of control differed signifi-
cantly between groups according to asthma maintenance
treatment received (Fischer’s exact test et p< 0.001); 46% of
children with optimal control received fixed combinations of
inhaled corticosteroids and long-acting b2-agonists vs 29% with
an unacceptable control.
Asthma control in children: ELIOS survey findings 1389The persistent poor quality of asthma control is all the
more remarkable given the numerous public health initia-
tives undertaken to raise awareness on the importance of
achieving satisfactory asthma control.3,4,8
Previous surveys have shown high proportions of unsat-
isfactory asthma control in children. A postal survey for
parents of 572 children with asthma in Switzerland per-
formed in 1998 revealed that only 18% of the children
achieved an excellent level of asthma control, with control
being unsatisfactory in 49%.9 The degree of control was
found to be associated with age, better control being
achieved in older children. For children of 13e16 years of
age, 34% had unsatisfactory control compared to 62% for
those aged 4e6 years. In the AIRE study performed in
Europe in 1999, the proportion of children requiring rescue
medication was 61.0%, and the proportion requiring an
unscheduled urgent care visit in the previous twelve
months was 36.0%.5 A recent observational survey of
asthma control in children and adult conducted in France in
20036 used a similar methodology to the ELIOS study. In the
ER’Asthme study, the proportion of children with asthma
optimally controlled was 27%, similar to the value reported
here. In contrast, the proportion of children whose asthma
was unacceptably controlled seems to have decreased from
66% in 2003 in the ER’Asthme study to 32.7% in the ELIOS
study. However, it should be noted that the control criteria
used in the two studies, although both based on the ANAES
criteria, differed slightly. For example, emergency
department visits were included in the ER’Asthme study
while school absenteeism was included in the ELIOS study.
Our study was conducted before the latest GINA guide-
lines.3 The threshold for symptom frequency and use of
rescue b-agonist to define acceptable control was four
times a week in the ANAES guidelines, while it was twice
a week as recommended in the new GINA guidelines.Therefore, this survey applying the GINA recommendations
would report more uncontrolled asthmatics.
The large sample size of the study (3431 children)
allowed including a large number of variables for a possible
association with the degree of asthma control using logistic
regression analysis. This identified respiratory tract infec-
tions, the number of associated allergies, the presence of
a smoker in the house, low socio-economic status and body
mass index as variables associated with poor asthma
control. An association between frequent respiratory tract
infections and asthma control10 and treatment refractori-
ness11 have been previously reported in adults and recently
in infants12 but not, to our knowledge, in children. With
respect to obesity, an association between high body mass
index and poor asthma control has been documented in
several studies in adults,6,13e15 although this relationship
seems less clear in children.16 Relationships between
overweight and asthma are still not completely under-
stood.17 One hypothesis is that asthma patients with higher
body mass index may respond less well to asthma control
treatments.15 On the other hand, the association between
asthma control and atopic disease is well documented in
both adults and children,18,19 and successful treatment of
atopic disease may improve asthma control.20 The associ-
ation between passive exposure to parental tobacco smoke
and poor asthma control in children has previously been
observed in other studies in France,6,21 USA,22 Canada23 and
Japan.24 An increased prevalence and severity of asthma in
children from homes where a parent smokes has been
reported from the National Health and Nutrition Examina-
tion Survey (NHANES) in the USA.25,26 A relationship
between poor control and low socio-economic level has
been described in both adults and children, mainly in North
America27e30 and in Europe as well.31 In France, this rela-
tionship persists despite the free coverage by CMU which
includes free access to drugs and medical advice. It is
important to note that low socio-economic status and
exposure to passive tobacco smoke were identified as inde-
pendent variables in our study and not related to the higher
proportion of smokers in lower socio-economic groups.
A potential weakness of our study is the lack of
systematic pulmonary function test. Indeed, FEV1 or PEFR
are parameters to be included when assessing asthma
control. This situation is not unique to France since the
AIRE study also revealed low take-up of respiratory function
testing in seven European countries, ranging from 13.5% in
the United Kingdom to 68.8% in Germany.32 A Canadian
study has also found that only 18% of patients with asthma
are tested for respiratory function.33 International guide-
lines recommend that respiratory function should be
routinely evaluated in order to adapt treatment in case of
inadequate asthma control.4 Our results also emphasise
that guidelines do not seem to be followed widely in
community care, since the PEFR was only documented for
a third of the children in this study. The two groups of
children with and without PEFR assessment were somewhat
different. The group of children in whom PEFR was evalu-
ated were older, heavier, with a longer history of asthma,
had more associated allergic diseases and a poorer control
during the previous 4 weeks. It is likely that the more
frequent symptoms influenced the physician to assess PEFR.
However, in this group, a lower proportion of children
1390 J. de Blic et al.fulfilled criteria for acceptable control when PEFR was
taken into account. While the sensitivity and the specificity
of PEFR variations in the assessment of asthma control are
arguable, our results suggest that the lack of PEFR assess-
ment by the physician during a consultation would under-
estimate the asthma control, and that PEFR would help the
clinician in deciding to step-up the treatment.
Our results provide further evidence that asthma treat-
ment in children does not comply with guidelines, notably
with inhaled corticosteroids being underused, particularly
in uncontrolled asthma.5,34
In our study, 83.3% of the children had an asthma main-
tenance treatment; despite that asthma control was unac-
ceptable in over half of them. Of the children receiving
a treatment, 71.2% were prescribed a recommended
therapy. The benefit of adding a LABA to an ICS, either in
a separate or fixed ICS/LABA combination, in improving
asthma control and treatment compliance has been
demonstrated in observational studies, such as ER’Asthme6
and in clinical studies.35e38 In our study, the proportion of
children with optimal asthma control was twice as high in
those using a fixed combination treatment compared to
children without a maintenance treatment. However, it is
difficult to draw definite conclusions from these results.
Indeed, the study was not designed for evaluation of asthma
severity but rather for evaluation of asthma control.
In conclusion, this analysis of 3431 children with asthma
treated in the community in France shows that asthma
control remains unsatisfactory, with around one-third of
children having an unacceptable level of control. Several
variables associated with the level of control were identi-
fied: notably allergic conditions, tobacco passive smoking
and low socio-economic status. Public health strategies
should increase awareness amongst physicians and parents
about the importance of using asthma control tools.
Adapting treatment to the level of control assessed, elim-
inating exposure to tobacco smoke and treating allergic
diseases39 are three practical measures that may have
a significant beneficial impact on the control of childhood
asthma.
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